Swiss vaccines company GlycoVaxyn has appointed Gerd Zettlmeissl as chairman of the board of directors with effect from June, when he will take over from Michel Greco.
“Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising company,” Greco said.
“Having chaired the board for more than seven years, I will work very closely with Gerd to ensure a smooth transition,” he added.
Zettlmeissl has more than 20 years of experience in developing and commercialising vaccines and spent almost 10 years in executive positions at Intercell.
He served first as its chief operating officer from 2001 to 2005 and then as CEO from 2005 until May 2011.
Prior to joining Intercell, Zettlmeissl served as international head of industrial and quality operations at Chiron Vaccines, and managing director of Chiron Behring GmbH & Co.
He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.